| US 7,338,960 B2 | ||
| Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators | ||
| Richard Bell, Stevenage (United Kingdom); Paul John Beswick, Harlow (United Kingdom); Romain Luc Marie Gosmini, Les Ulls (France); Richard Martin Grimes, Stevenage (United Kingdom); Christopher Charles Frederick Hamlett, Stevenage (United Kingdom); Nigel Paul King, Harlow (United Kingdom); and Vipulkumar Kantibhai Patel, Stevenage (United Kingdom) | ||
| Assigned to SmithKline Beecham Corporation, Philadelphia, Pa. (US) | ||
| Appl. No. 10/518,679 PCT Filed Jun. 18, 2003, PCT No. PCT/EP03/06415 § 371(c)(1), (2), (4) Date Aug. 16, 2005, PCT Pub. No. WO04/000315, PCT Pub. Date Dec. 31, 2003. |
||
| Claims priority of application No. 0214149.7 (GB), filed on Jun. 19, 2002. | ||
| Prior Publication US 2006/0089394 A1, Apr. 27, 2006 | ||
| Int. Cl. A61K 31/435 (2006.01); A61K 31/12 (2006.01); C07C 59/00 (2006.01); C07D 211/70 (2006.01) | ||
| U.S. Cl. 514—277 [514/683; 562/465; 562/471; 546/339] | 14 Claims |
1. A compound of formula (I) or a pharmaceutically acceptable salt, or hydrolysable ester thereof,
 wherein:
R1 and R2 are independently H or C1-3 alkyl;
X represents a O or (CH2)n where n is 0, 1 or 2;
R3 and R4 independently represent H, C1-3 alkyl, —OCH3, —CF3, allyl, or halogen;
X1 represents O, S, SO2, SO, or CH2;
R5 and R6 independently represent hydrogen, C1-6 alkyl (including branched alkyl and optionally substituted by one or more halogens or C1-6alkoxy), or together with the carbon atom to which they are bonded form a 3-6 membered cycloalkyl ring; and
R7 is
 wherein R is para —C6H4CF3, para —C6H4Me, para —C6H4CN or para —C6H4Cl.
|